Ablynx spikes as PhIII aTTP study comes through with promising data, setting up an FDA application
Ablynx shares {$ABLX BB} surged 25% this morning after the Belgian biotech reported that its lead drug for an ultra-rare blood clotting disease hit the primary and two key secondary endpoints in the pivotal Phase III study. And with the European application already under review with the mid-stage results, Ablynx says it will line up a US filing planned for next year.
The drug caplacizumab targets acquired thrombotic thrombocytopenic purpura (aTTP), a disorder that triggers low platelet counts. In the Phase III study, researchers reported top-line results that included a significant (p=0.01) reduction in the time it took for the platelet counts to return to normal for the drug arm — a likely indicator for the prevention of microvascular thrombosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.